Celebrex Long-Term Safety Monitoring Results Reassure FDA
Executive Summary
Data from long-term Celebrex (celecoxib) post-marketing studies reassure FDA of the COX-2 inhibitor's safety, Acting Deputy Commissioner for Operations Janet Woodcock, MD, said
You may also be interested in...
Merck Sets $604 Mil. Vioxx Legal Defense Reserve; PR Battles Continue
Merck will take a $604 mil. charge in the fourth quarter to establish a reserve for its defense of Vioxx litigation, an amount roughly equivalent to Singulair quarterly sales
Merck Sets $604 Mil. Vioxx Legal Defense Reserve; PR Battles Continue
Merck will take a $604 mil. charge in the fourth quarter to establish a reserve for its defense of Vioxx litigation, an amount roughly equivalent to Singulair quarterly sales
Pfizer Tells Doctors To Consider COX-2 Alternatives; DTC Ads Are Halted
Pfizer is revising Celebrex and Bextra professional promotions at FDA's request to include suggestions that physicians consider alternative therapies on an individual patient basis